阿氯米松(Alclometasone Dipropionate) - 药物靶点：GR_在研适应症：瘙痒，皮炎，湿疹_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Alclometasone、Alclometasone dipropionate (JAN/USP)

+ [11]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

免疫系统疾病感染遗传病与畸形+ [3]

在研适应症

瘙痒皮炎湿疹+ [9]

非在研适应症

嗜皮菌病

原研机构

Fougera Pharmaceuticals, Inc.

在研机构

Shionogi & Co., Ltd.

Aspire Pharma Ltd.

非在研机构

Fougera Pharmaceuticals, Inc.

重庆华邦制药有限公司

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1982-12-14),

嗜皮菌病

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构/序列

分子式C28H37ClO7

InChIKeyDJHCCTTVDRAMEH-DUUJBDRPSA-N

CAS号66734-13-2

关联

2

项与阿氯米松相关的临床试验

NCT01465802

/ Completed临床2期

ARCHER 1042: A PHASE 2 STUDY OF DACOMITINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (POST-CHEMOTHERAPY OR SELECT FIRST LINE PATIENTS) TO EVALUATE PROPHYLACTIC INTERVENTION ON DERMATOLOGIC AND GASTROINTESTINAL ADVERSE EVENTS AND PATIENT REPORTED OUTCOMES

To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).

开始日期2011-12-26

申办/合作机构

Pfizer Inc.

NCT02075632

/ Completed临床2期

A Mult-Center, Open-Label Study to Evaluate Product Duration of Use Experience With Aclometasone Diproprionate Cream

This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who would use OTC treatments for relief. The study population will be composed of two different cohorts: chronic condition sufferers (eczema or psoriasis) and participants who suffer from occasional itchy skin experiences (such as poison ivy, oak, sumac, insect bites, or skin irritations due to jewelry, cosmetics, detergents, or soaps) where an anti-itch medication would be used.

开始日期2006-09-01

申办/合作机构

GSK Plc

100 项与阿氯米松相关的临床结果

登录后查看更多信息

100 项与阿氯米松相关的转化医学

登录后查看更多信息

100 项与阿氯米松相关的专利（医药）

登录后查看更多信息

117

项与阿氯米松相关的文献（医药）

2024-07-08·Journal of Chemical Information and Modeling

DrugSK: A Stacked Ensemble Learning Framework for Predicting Drug Combinations of Multiple Diseases

Article

作者: Guan, Jibin ; Chen, Siqi ; Jiang, Xiwei ; Ling, Guixia ; Li, Kefeng ; Zhang, Peng ; Zhai, Fei ; Gao, Nan ; Xiang, Rongwu ; Li, Chunzhi

Combination therapy is an important direction of continuous exploration in the field of medicine, with the core goals of improving treatment efficacy, reducing adverse reactions, and optimizing clinical outcomes. Machine learning technology holds great promise in improving the prediction of drug synergy combinations. However, most studies focus on single disease-oriented collaborative predictive models or involve excessive feature categories, making it challenging to predict the majority of new drugs. To address these challenges, the DrugSK comprehensive model was developed, which utilizes SMILES-BERT to extract structural information from 3492 drugs and trains on reactions from 48,756 drug combinations. DrugSK is an integrated learning model capable of predicting interactions among various drug categories. First, the primary learner is trained from the initial data set. Random forest, support vector machine, and XGboost model are selected as primary learners and logistic regression as secondary learners. A new data set is then "generated" to train level 2 learners, which can be thought of as a prediction for each model. Finally, the results are filtered using logistic regression. Furthermore, the combination of the new antibacterial drug Drafloxacin with other antibacterial agents was tested. The synergistic effect of Drafloxacin and Isavuconazonium in the fight against Candida albicans has been confirmed, providing enlightenment for the clinical treatment of skin infection. DrugSK's prediction is accurate in practical application and can also predict the probability of the outcome. In addition, the tendency of Drafloxacin and antifungal drugs to be synergistic was found. The development of DrugSK will provide a new blueprint for predicting drug combination synergies.

2024-03-01·Journal of Chromatography A

Simultaneous determination of 58 glucocorticoid residues in milk by ultra-high performance liquid chromatography-tandem mass spectrometry

Article

作者: Chen, Sumeng ; Chen, Gang ; Guo, Can ; Tan, Sijia ; Zhang, Zihao ; Wu, Cuiling

Abuse of glucocorticoid veterinary drugs in dairy industry can potentially threat milk safety and consequently influence human health. Here a reliable method for determination of 58 glucocorticoid drug residues in milk was established by combining solid phase extraction with ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The analytes were extracted with acetonitrile and cleanup with EMR-Lipid lipid removal column. The analytes were chromatographically separated using Poroshell EC-C₁₈ column and acquired by electrospray ionization with multiple-reaction monitoring (MRM) mode. The limit of quantification (S/N ≥ 10) ranged from 0.2 to 2.0 µg/kg and the limit of detection (S/N ≥ 3) ranged from 0.1 to 1.0 µg/kg. Average recoveries were from 71% to 113%, the relative standard deviations (RSDs) were less than 15%, and the correlation coefficients (R²) of calibration curves exceeded 0.99. The method was applied to detect twenty milk products obtained from local supermarkets including ten pasteurized milk and ten UHT milk. Two endogenous glucocorticoids, i.e. hydrocortisone and cortisone were detected but not exceed the maximum residue limits (MRLs).

2024-01-01·Traffic

Glucocorticoids rescue cell surface trafficking of R451C Neuroligin3 and enhance synapse formation

Article

作者: De Jaco, Antonella ; Comoletti, Davide ; Bianchi, Sara ; Miranda, Elena ; Trobiani, Laura ; Di Angelantonio, Silvia ; Sollazzo, Raimondo ; Lauro, Clotilde ; Giorda, Ezio ; Serafini, Federica ; Guglielmo, Stefano ; Ragozzino, Davide ; Perfetto, Camilla ; Ferrucci, Laura ; Diamanti, Tamara ; Gioia, Roberta ; Setini, Andrea ; Cacci, Emanuele ; Mautone, Lorenza

AbstractNeuroligins are synaptic cell adhesion proteins with a role in synaptic function, implicated in neurodevelopmental disorders. The autism spectrum disorder‐associated substitution Arg451Cys (R451C) in NLGN3 promotes a partial misfolding of the extracellular domain of the protein leading to retention in the endoplasmic reticulum (ER) and the induction of the unfolded protein response (UPR). The reduced trafficking of R451C NLGN3 to the cell surface leads to altered synaptic function and social behavior. A screening in HEK‐293 cells overexpressing NLGN3 of 2662 compounds (FDA‐approved small molecule drug library), led to the identification of several glucocorticoids such as alclometasone dipropionate, desonide, prednisolone sodium phosphate, and dexamethasone (DEX), with the ability to favor the exit of full‐length R451C NLGN3 from the ER. DEX improved the stability of R451C NLGN3 and trafficking to the cell surface, reduced the activation of the UPR, and increased the formation of artificial synapses between HEK‐293 and hippocampal primary neurons. The effect of DEX was validated on a novel model system represented by neural stem progenitor cells and differentiated neurons derived from the R451C NLGN3 knock‐in mouse, expressing the endogenous protein. This work shows a potential rescue strategy for an autism‐linked mutation affecting cell surface trafficking of a synaptic protein.

100 项与阿氯米松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01820	阿氯米松	D07AB10 S01BA10	DB00240

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
瘙痒	英国	Aspire Pharma Ltd.	1995-04-26
皮炎	日本	Shionogi & Co., Ltd.	1988-03-29
湿疹	日本	Shionogi & Co., Ltd.	1988-03-29
红斑	日本	Shionogi & Co., Ltd.	1988-03-29
昆虫咬伤和螫伤	日本	Shionogi & Co., Ltd.	1988-03-29
掌跖角化病	日本	Shionogi & Co., Ltd.	1988-03-29
扁平苔藓	日本	Shionogi & Co., Ltd.	1988-03-29
盘状红斑狼疮	日本	Shionogi & Co., Ltd.	1988-03-29
痒疹	日本	Shionogi & Co., Ltd.	1988-03-29
银屑病	日本	Shionogi & Co., Ltd.	1988-03-29
紫癜	日本	Shionogi & Co., Ltd.	1988-03-29
蔷薇疹病毒感染	日本	Shionogi & Co., Ltd.	1988-03-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01465802 (ARCHER 1042, CTgov)	临床2期	晚期非小细胞肺癌	236	Placebo+Doxycycline+Dacomitinib (Cohort I: Arm A (Dacomitinib 45 mg + Doxycycline Placebo))	鹹製淵淵憲鹹鏇鏇願鏇(獵廠艱蓋廠壓淵夢衊艱) = 鏇襯鹹壓鬱襯鹹獵範襯鏇窪鬱簾齋獵廠獵鏇鏇 (鑰窪餘鬱鹹窪鑰膚積願, 淵構繭簾觸鏇襯鑰顧觸 ~ 餘憲餘糧選鬱膚夢繭遞) 更多	-	2016-08-17
				Doxycycline+Dacomitinib (Cohort I: Arm B (Dacomitinib 45 mg + Doxycycline 100 mg))	鹹製淵淵憲鹹鏇鏇願鏇(獵廠艱蓋廠壓淵夢衊艱) = 憲艱顧觸鏇廠憲繭遞鑰鏇窪鬱簾齋獵廠獵鏇鏇 (鑰窪餘鬱鹹窪鑰膚積願, 淵構壓夢網鹽簾選鏇窪 ~ 繭簾窪積艱獵範襯鏇遞) 更多
NCT01465802 (ARCHER 1042, WCLC2015)	临床2期	晚期非小细胞肺癌	112	Dacomitinib 45 mg + placebo	構鬱繭鑰遞獵艱憲鏇鏇(獵鹹蓋願願淵觸窪網廠) = improved with prophylactic doxy, but not alclo; prophylactic probiotic was not associated with improved CTCAE or PRO 壓憲鬱構憲齋糧鏇簾蓋 (淵壓鹽衊鹹廠淵鬱鏇窪 )	-	2015-09-08
				Dacomitinib 45 mg + Doxycycline 100 mg